Products for Research Use Only
RegisterLogin

BCTC

CAT: 0804-HY-19960-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19960-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1) . BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects[1][2][3][4][5].
CAS Number
393514-24-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CGRP Receptor; Insulin Receptor; TRP Channel
Type
Reference compound
Related Pathways
GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer; Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/BCTC.html
Purity
99.66
Solubility
DMSO : ≥ 50 mg/mL
Smiles
O=C(N1CCN(C2=NC=CC=C2Cl)CC1)NC3=CC=C(C(C)(C)C)C=C3
Molecular Formula
C20H25ClN4O
Molecular Weight
372.89
Precautions
H302, H315, H319, H335
References & Citations
[1]Liu T, et al. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2016 Jan;11 (1) :182-188. |[2] Pomonis JD, et al. N- (4-Tertiarybutylphenyl) -4- (3-cholorphyridin-2-yl) tetrahydropyrazine -1 (2H) -carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003 Jul;306 (1) :387-93.|[3]Kanai Y, et al. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology. 2005 Dec;49 (7) :977-84. |[4] Nie C, et al. Study on chemical modification and analgesic activity of N- (4-tert-butylphenyl) -4- (3-chloropyridin-2-yl) piperazine-1-carboxamide. Eur J Med Chem. 2020 May 15;194:112236. |[5]Tanaka H, et al. Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci. 2011 Mar 14;88 (11-12) :559-63.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-117683BCTP

Alternative Products

CatalogName
BB165272-01BCTC

Popular Products